

PATENT IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
( Case No. 04-372 (400.137) )

In the Application of:

McSwiggen et al.

Serial No.: 10/698,311

Filing Date: October 31, 2003

For: RNA Interference Mediated Treatment of  
Parkinson Disease Using Short Interfering  
Nucleic Acid (SINA)



Examiner: TBD

Group Art Unit: 1632

Confirmation No.: 9826

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:


- ☒ Second Supplemental Information Disclosure Statement;
- ☒ Second Supplemental Information Disclosure Statement (IDS) PTO-1449 Form;
- ☒ Copies of IDS Citations for S/N 10/698,311 (Total 14 foreign patents and 3 other documents); and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on 6-8 2005.

By :

  
Lisa M.W. Hillman  
Reg. No. 43,673

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP  
300 SOUTH WACKER DRIVE  
CHICAGO, ILLINOIS 60606  
TELEPHONE (312) 913-0001  
FACSIMILE: (312) 913-0002



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
( Case No. 04-372 (400.137) )**

<b>In the Application of:</b>	)	
	)	
<b>McSwiggen et al.</b>	)	
	)	<b>Examiner: TBD</b>
<b>Serial No.: 10/698,311</b>	)	
	)	<b>Group Art Unit: 1632</b>
<b>Filing Date: October 31, 2003</b>	)	
	)	<b>Confirmation No.: 9826</b>
<b>For: RNA Interference Mediated Treatment of )</b>		
<b>Parkinson Disease Using Short Interfering )</b>		
<b>Nucleic Acid (SINA) )</b>		

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a

representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.


Respectfully submitted,

**McDonnell Boehnen Hulbert & Berghoff**

Date:

6-8

2005 By:

A handwritten signature in black ink, appearing to read "Lisa M.W. Hillman", written over a horizontal line.

Lisa M.W. Hillman

Reg. No. 43,673

McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive, 32<sup>nd</sup> Floor  
Chicago, IL 60606  
Telephone: 312-913-0001  
Facsimile: 312-913-0002

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-372  
(400/137)

Serial No.

10/698,311

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**Applicant:**

McSwiggen et al.

**Filing Date:**

October 31, 2003

**Group:**

1632

**U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US 2003/0190635	10/2003	McSwiggen et al.			
	*	US 2003/0206887	11/2003	Morrissey et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
*	1.	1325955	07/09/03	EP (Klippel-Giese et al.)				
	2.	95/04142	02/09/95	WO (Robinson)				
*	3.	99/04819	02/04/99	WO (Klimuk et al.)				
	4.	99/55857	11/04/99	WO (Beigelman et al.)				
	5.	01/097850	12/27/01	WO (Siemeister et al.)				
	6.	02/07747	01/31/02	WO (King)				
	7.	02/10378	02/07/02	WO (Cowsert et al.)				
	8.	02/096927	12/05/02	WO (Escobedo et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-372  
(400/137)

Serial No.

10/698,311



SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

October 31, 2003

Group:

1632

9.	03/068797	08/21/03	WO (Rossi et al.)				
10.	03/070910	08/28/03	WO (McSwiggen et al.)				
11.	03/080638	10/02/03	WO (Lacasse et al.)				
12.	04/043977	05/27/04	WO (Prakush et al.)				
13.	04/072261	08/26/04	WO (Li et al.)				
16.	08208687	08/1996	JP (Hotoda et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

14.	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," Oligonucleotides, 13:303-312 (2003)
17.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
15.	International Search Report for PCT/US2004/016390 mailed March 31, 2005

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.